In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme 4 selected

Guidance programme

Showing 281 to 290 of 294

TitleTypeExpected publication date
Venglustat for treating gangliosidoses in people 2 years and over ID 6358Technology appraisal guidanceTBC
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]Technology appraisal guidanceTBC
Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6382]Technology appraisal guidanceTBC
Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable TSID 12099Technology appraisal guidanceTBC
Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]Technology appraisal guidanceTBC
Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407]Technology appraisal guidanceTBC
Vosoritide for treating achondroplasia in people 4 months and over ID6488Technology appraisal guidanceTBC
Vutrisiran for treating transthyretin-related amyloidosis cardiomyopathy [ID6470]Technology appraisal guidance
Waldenstrom's macroglobulinaemia - ibrutinib [ID884]Technology appraisal guidance
Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All